Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2004

Open Access 01-12-2004 | Review

Antiangiogenic gene therapy of cancer: recent developments

Authors: Anita Tandle, Dan G Blazer III, Steven K Libutti

Published in: Journal of Translational Medicine | Issue 1/2004

Login to get access

Abstract

With the role of angiogenesis in tumor growth and progression firmly established, considerable effort has been directed to antiangiogenic therapy as a new modality to treat human cancers. Antiangiogenic agents have recently received much widespread attention but strategies for their optimal use are still being developed. Gene therapy represents an attractive alternative to recombinant protein administration for several reasons. This review evaluates the potential advantages of gene transfer for antiangiogenic cancer therapy and describes preclinical gene transfer work with endogenous angiogenesis inhibitors demonstrating the feasibility of effectively suppressing and even eradicating tumors in animal models. Additionally, we describe the advantages and disadvantages of currently available gene transfer vectors and update novel developments in this field. In conclusion, gene therapy holds great promise in advancing antiangiogenesis as an effective cancer therapy and will undoubtedly be evaluated in human clinical trials in the near future.
Appendix
Available only for authorised users
Literature
1.
Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971, 285: 1182-1186.PubMed
2.
Satchi-Fainaro R, Puder M, Davies JW, Tran HT, Sampson DA, Greene AK, Corfas G, Folkman J: Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med. 2004, 10: 255-261. 10.1038/nm1002.PubMed
3.
Ribatti D, Vacca A, Presta M: The discovery of angiogenic factors: a historical review. Gen Pharmacol. 2000, 35: 227-231. 10.1016/S0306-3623(01)00112-4.PubMed
4.
Folkman J, Klagsbrun M: Angiogenic factors. Science. 1987, 235: 442-447.PubMed
5.
Dameron KM, Volpert OV, Tainsky MA, Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 1994, 265: 1582-1584.PubMed
6.
Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE: Halting angiogenesis suppresses carcinoma cell invasion. Nat Med. 1997, 3: 1222-1227.PubMed
7.
Volpert OV, Dameron KM, Bouck N: Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene. 1997, 14: 1495-1502. 10.1038/sj.onc.1200977.PubMed
8.
Bertolini F, Mancuso P, Gobbi A, Pruneri G: The thin red line: angiogenesis in normal and malignant hematopoiesis. Exp Hematol. 2000, 28: 993-1000. 10.1016/S0301-472X(00)00508-7.PubMed
9.
Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995, 1: 149-153.PubMed
10.
Breakthrough of the year. The runners-up. Science. 2003, 302: 2039-2045. 10.1126/science.302.5653.2039.
11.
Sedlacek HH: Pharmacological aspects of targeting cancer gene therapy to endothelial cells. Crit Rev Oncol Hematol. 2001, 37: 169-215. 10.1016/S1040-8428(00)00113-X.PubMed
12.
Vartanian RK, Weidner N: Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am J Pathol. 1994, 144: 1188-1194.PubMedCentralPubMed
13.
Boehm T, Folkman J, Browder T, O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997, 390: 404-407. 10.1038/37126.PubMed
14.
Dixelius J, Larsson H, Sasaki T, Holmqvist K, Lu L, Engstrom A, Timpl R, Welsh M, Claesson-Welsh L: Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood. 2000, 95: 3403-3411.PubMed
15.
Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 1999, 284: 808-812. 10.1126/science.284.5415.808.PubMed
16.
Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R: Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003, 300: 1155-1159. 10.1126/science.1082504.PubMed
17.
Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000, 60: 1878-1886.PubMed
18.
Folkman J: Angiogenesis and apoptosis. Semin Cancer Biol. 2003, 13: 159-167. 10.1016/S1044-579X(02)00133-5.PubMed
19.
Gasparini G: Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. Crit Rev Oncol Hematol. 2001, 37: 97-114. 10.1016/S1040-8428(00)00105-0.PubMed
20.
Munshi NC, Wilson C: Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol. 2001, 28: 565-569. 10.1053/sonc.2001.28954.PubMed
21.
Hlatky L, Hahnfeldt P, Folkman J: Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst. 2002, 94: 883-893. 10.1093/jnci/94.12.883.PubMed
22.
Mancuso P, Calleri A, Cassi C, Gobbi A, Capillo M, Pruneri G, Martinelli G, Bertolini F: Circulating endothelial cells as a novel marker of angiogenesis. Adv Exp Med Biol. 2003, 522: 83-97.PubMed
23.
Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL: Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci U S A. 2000, 97: 14608-14613. 10.1073/pnas.97.26.14608.PubMedCentralPubMed
24.
Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, Schatteman GC, Seftor RE: Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci U S A. 2001, 98: 8018-8023. 10.1073/pnas.131209798.PubMedCentralPubMed
25.
Hendrix MJ, Seftor EA, Hess AR, Seftor RE: Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer. 2003, 3: 411-421. 10.1038/nrc1092.PubMed
26.
Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent JM, Meltzer PS, Hendrix MJ: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999, 155: 739-752.PubMedCentralPubMed
27.
Thies A, Mangold U, Moll I, Schumacher U: PAS-positive loops and networks as a prognostic indicator in cutaneous malignant melanoma. J Pathol. 2001, 195: 537-542. 10.1002/path.988.PubMed
28.
Makitie T, Summanen P, Tarkkanen A, Kivela T: Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst. 1999, 91: 359-367. 10.1093/jnci/91.4.359.PubMed
29.
Kerbel R, Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002, 2: 727-739. 10.1038/nrc905.PubMed
30.
Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E, Fogler WE, Sim BK, Allred EN, Pirie-Shepherd SR, Folkman J: Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 2001, 61: 7669-7674.PubMed
31.
Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003, 3: 401-410. 10.1038/nrc1093.PubMed
32.
Folkman J, Kalluri R: Cancer without disease. Nature. 2004, 427: 787-10.1038/427787a.PubMed
33.
Marx J: Angiogenesis. A boost for tumor starvation. Science. 2003, 301: 452-454. 10.1126/science.301.5632.452.PubMed
34.
Liau G, Su EJ, Dixon KD: Clinical efforts to modulate angiogenesis in the adult: gene therapy versus conventional approaches. Drug Discov Today. 2001, 6: 689-697. 10.1016/S1359-6446(01)01809-8.PubMed
35.
Volpert OV, Alani RM: Wiring the angiogenic switch: Ras, Myc, and Thrombospondin-1. Cancer Cell. 2003, 3: 199-200. 10.1016/S1535-6108(03)00056-4.PubMed
36.
de Fraipont F, Nicholson AC, Feige JJ, Van Meir EG: Thrombospondins and tumor angiogenesis. Trends Mol Med. 2001, 7: 401-407. 10.1016/S1471-4914(01)02102-5.PubMed
37.
Vailhe B, Feige JJ: Thrombospondins as anti-angiogenic therapeutic agents. Curr Pharm Des. 2003, 9: 583-588.PubMed
38.
Jin RJ, Kwak C, Lee SG, Lee CH, Soo CG, Park MS, Lee E, Lee SE: The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts. Cancer Gene Ther. 2000, 7: 1537-1542. 10.1038/sj.cgt.7700266.PubMed
39.
Liu P, Wang Y, Li YH, Yang C, Zhou YL, Li B, Lu SH, Yang RC, Cai YL, Tobelem G, Caen J, Han ZC: Adenovirus-mediated gene therapy with an antiangiogenic fragment of thrombospondin-1 inhibits human leukemia xenograft growth in nude mice. Leuk Res. 2003, 27: 701-708. 10.1016/S0145-2126(02)00346-6.PubMed
40.
O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997, 88: 277-285. 10.1016/S0092-8674(00)81848-6.PubMed
41.
Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, Yang C, Hynes RO, Werb Z, Sudhakar A, Kalluri R: Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell. 2003, 3: 589-601. 10.1016/S1535-6108(03)00133-8.PubMedCentralPubMed
42.
Kim YM, Hwang S, Pyun BJ, Kim TY, Lee ST, Gho YS, Kwon YG: Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem. 2002, 277: 27872-27879. 10.1074/jbc.M202771200.PubMed
43.
Hanai J, Dhanabal M, Karumanchi SA, Albanese C, Waterman M, Chan B, Ramchandran R, Pestell R, Sukhatme VP: Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem. 2002, 277: 16464-16469. 10.1074/jbc.M112274200.PubMed
44.
Folkman J: Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther. 2003, 2: S127-33.PubMed
45.
Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, Pluda J, Hong WK, Abbruzzese JL: Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2002, 20: 3792-3803. 10.1200/JCO.2002.11.061.PubMed
46.
Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, Tutsch K, Dresen A, Geiger P, Pluda J, Fogler W, Schiller JH, Wilding G: Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2003, 21: 223-231. 10.1200/JCO.2003.12.120.PubMed
47.
Feldman AL, Restifo NP, Alexander HR, Bartlett DL, Hwu P, Seth P, Libutti SK: Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res. 2000, 60: 1503-1506.PubMedCentralPubMed
48.
Feldman AL, Alexander HR, Hewitt SM, Lorang D, Thiruvathukal CE, Turner EM, Libutti SK: Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors. J Natl Cancer Inst. 2001, 93: 1014-1020. 10.1093/jnci/93.13.1014.PubMed
49.
Kalluri R: Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer. 2003, 3: 422-433. 10.1038/nrc1094.PubMed
50.
Maeshima Y, Colorado PC, Torre A, Holthaus KA, Grunkemeyer JA, Ericksen MB, Hopfer H, Xiao Y, Stillman IE, Kalluri R: Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem. 2000, 275: 21340-21348. 10.1074/jbc.M001956200.PubMed
51.
Maeshima Y, Colorado PC, Kalluri R: Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem. 2000, 275: 23745-23750. 10.1074/jbc.C000186200.PubMed
52.
Maeshima Y, Manfredi M, Reimer C, Holthaus KA, Hopfer H, Chandamuri BR, Kharbanda S, Kalluri R: Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J Biol Chem. 2001, 276: 15240-15248. 10.1074/jbc.M007764200.PubMed
53.
Colorado PC, Torre A, Kamphaus G, Maeshima Y, Hopfer H, Takahashi K, Volk R, Zamborsky ED, Herman S, Sarkar PK, Ericksen MB, Dhanabal M, Simons M, Post M, Kufe DW, Weichselbaum RR, Sukhatme VP, Kalluri R: Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res. 2000, 60: 2520-2526.PubMed
54.
Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, Torre A, Maeshima Y, Mier JW, Sukhatme VP, Kalluri R: Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem. 2000, 275: 1209-1215. 10.1074/jbc.275.2.1209.PubMed
55.
Xu R, Yao ZY, Xin L, Zhang Q, Li TP, Gan RB: NC1 domain of human type VIII collagen (alpha 1) inhibits bovine aortic endothelial cell proliferation and causes cell apoptosis. Biochem Biophys Res Commun. 2001, 289: 264-268. 10.1006/bbrc.2001.5970.PubMed
56.
Ramchandran R, Dhanabal M, Volk R, Waterman MJ, Segal M, Lu H, Knebelmann B, Sukhatme VP: Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun. 1999, 255: 735-739. 10.1006/bbrc.1999.0248.PubMed
57.
O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Cao Y, Moses M, Lane WS, Sage EH, Folkman J: Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol. 1994, 59: 471-482.PubMed
58.
O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994, 79: 315-328. 10.1016/0092-8674(94)90200-3.PubMed
59.
O'Reilly MS, Holmgren L, Chen C, Folkman J: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 1996, 2: 689-692.PubMed
60.
Wahl ML, Moser TL, Pizzo SV: Angiostatin and Anti-angiogenic Therapy in Human Disease. Recent Prog Horm Res. 2004, 59: 73-104. 10.1210/rp.59.1.73.PubMed
61.
Beerepoot LV, Witteveen EO, Groenewegen G, Fogler WE, Sim BK, Sidor C, Zonnenberg BA, Schramel F, Gebbink MF, Voest EE: Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study. Clin Cancer Res. 2003, 9: 4025-4033.PubMed
62.
Lalani AS, Chang B, Lin J, Case SS, Luan B, Wu-Prior WW, VanRoey M, Jooss K: Anti-tumor efficacy of human angiostatin using liver-mediated adeno-associated virus gene therapy. Mol Ther. 2004, 9: 56-66. 10.1016/j.ymthe.2003.10.001.PubMed
63.
Galaup A, Opolon P, Bouquet C, Li H, Opolon D, Bissery MC, Tursz T, Perricaudet M, Griscelli F: Combined effects of docetaxel and angiostatin gene therapy in prostate tumor model. Mol Ther. 2003, 7: 731-740. 10.1016/S1525-0016(03)00121-7.PubMed
64.
Clapp C, Martial JA, Guzman RC, Rentier-Delure F, Weiner RI: The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology. 1993, 133: 1292-1299. 10.1210/en.133.3.1292.PubMed
65.
Tabruyn SP, Sorlet CM, Rentier-Delrue F, Bours V, Weiner RI, Martial JA, Struman I: The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappaB. Mol Endocrinol. 2003, 17: 1815-1823. 10.1210/me.2003-0132.PubMed
66.
Kim J, Luo W, Chen DT, Earley K, Tunstead J, Yu-Lee LY, Lin SH: Antitumor activity of the 16-kDa prolactin fragment in prostate cancer. Cancer Res. 2003, 63: 386-393.PubMed
67.
Bentzien F, Struman I, Martini JF, Martial J, Weiner R: Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice. Cancer Res. 2001, 61: 7356-7362.PubMed
68.
Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF, Sharpe RJ: Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science. 1990, 247: 77-79.PubMed
69.
Sharpe RJ, Byers HR, Scott CF, Bauer SI, Maione TE: Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst. 1990, 82: 848-853.PubMed
70.
Kolber DL, Knisely TL, Maione TE: Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. J Natl Cancer Inst. 1995, 87: 304-309.PubMed
71.
Belman N, Bonnem EM, Harvey HA, Lipton A: Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced colorectal carcinoma. Invest New Drugs. 1996, 14: 387-389.PubMed
72.
Tanaka T, Manome Y, Wen P, Kufe DW, Fine HA: Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med. 1997, 3: 437-442.PubMed
73.
Li Y, Jin Y, Chen H, Jie G, Tobelem G, Caen JP, Han ZC: Suppression of tumor growth by viral vector-mediated gene transfer of N-terminal truncated platelet factor 4. Cancer Biother Radiopharm. 2003, 18: 829-840. 10.1089/108497803770418373.PubMed
74.
Neville LF, Mathiak G, Bagasra O: The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev. 1997, 8: 207-219. 10.1016/S1359-6101(97)00015-4.PubMed
75.
Feldman AL, Friedl J, Lans TE, Libutti SK, Lorang D, Miller MS, Turner EM, Hewitt SM, Alexander HR: Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer. 2002, 99: 149-153. 10.1002/ijc.10292.PubMed
76.
Jones PF: Not just angiogenesis--wider roles for the angiopoietins. J Pathol. 2003, 201: 515-527. 10.1002/path.1452.PubMed
77.
Lin P, Buxton JA, Acheson A, Radziejewski C, Maisonpierre PC, Yancopoulos GD, Channon KM, Hale LP, Dewhirst MW, George SE, Peters KG: Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci U S A. 1998, 95: 8829-8834. 10.1073/pnas.95.15.8829.PubMedCentralPubMed
78.
Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003, 3: 133-146. 10.1038/nri1001.PubMed
79.
Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J: Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 1995, 87: 581-586.PubMed
80.
Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993, 178: 1223-1230. 10.1084/jem.178.4.1223.PubMed
81.
Portielje JE, Kruit WH, Schuler M, Beck J, Lamers CH, Stoter G, Huber C, de Boer-Dennert M, Rakhit A, Bolhuis RL, Aulitzky WE: Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin Cancer Res. 1999, 5: 3983-3989.PubMed
82.
Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB: Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res. 2000, 6: 1678-1692.PubMed
83.
Hurteau JA, Blessing JA, DeCesare SL, Creasman WT: Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol Oncol. 2001, 82: 7-10. 10.1006/gyno.2001.6255.PubMed
84.
Mazzolini G, Prieto J, Melero I: Gene therapy of cancer with interleukin-12. Curr Pharm Des. 2003, 9: 1981-1991.PubMed
85.
Caruso M, Pham-Nguyen K, Kwong YL, Xu B, Kosai KI, Finegold M, Woo SL, Chen SH: Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci U S A. 1996, 93: 11302-11306. 10.1073/pnas.93.21.11302.PubMedCentralPubMed
86.
Cao R, Farnebo J, Kurimoto M, Cao Y: Interleukin-18 acts as an angiogenesis and tumor suppressor. Faseb J. 1999, 13: 2195-2202.PubMed
87.
Nagai H, Hara I, Horikawa T, Oka M, Kamidono S, Ichihashi M: Gene transfer of secreted-type modified interleukin-18 gene to B16F10 melanoma cells suppresses in vivo tumor growth through inhibition of tumor vessel formation. J Invest Dermatol. 2002, 119: 541-548. 10.1046/j.1523-1747.2002.01866.x.PubMed
88.
Liu Y, Huang H, Saxena A, Xiang J: Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors. Cancer Gene Ther. 2002, 9: 533-542. 10.1038/sj.cgt.7700466.PubMed
89.
Sidky YA, Borden EC: Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 1987, 47: 5155-5161.PubMed
90.
Dvorak HF, Gresser I: Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst. 1989, 81: 497-502.PubMed
91.
Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ: Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A. 1995, 92: 4562-4566.PubMedCentralPubMed
92.
Lindner DJ: Interferons as antiangiogenic agents. Curr Oncol Rep. 2002, 4: 510-514.PubMed
93.
Albini A, Marchisone C, Del Grosso F, Benelli R, Masiello L, Tacchetti C, Bono M, Ferrantini M, Rozera C, Truini M, Belardelli F, Santi L, Noonan DM: Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy approach. Am J Pathol. 2000, 156: 1381-1393.PubMedCentralPubMed
94.
Berger AC, Alexander HR, Tang G, Wu PS, Hewitt SM, Turner E, Kruger E, Figg WD, Grove A, Kohn E, Stern D, Libutti SK: Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis. Microvasc Res. 2000, 60: 70-80. 10.1006/mvre.2000.2249.PubMed
95.
Wu PC, Alexander HR, Huang J, Hwu P, Gnant M, Berger AC, Turner E, Wilson O, Libutti SK: In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). Cancer Res. 1999, 59: 205-212.PubMed
96.
Gnant MF, Berger AC, Huang J, Puhlmann M, Wu PC, Merino MJ, Bartlett DL, Alexander H. R., Jr., Libutti SK: Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus. Cancer Res. 1999, 59: 4668-4674.PubMed
97.
Jiang Y, Goldberg ID, Shi YE: Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene. 2002, 21: 2245-2252. 10.1038/sj.onc.1205291.PubMed
98.
Wang M, Liu YE, Greene J, Sheng S, Fuchs A, Rosen EM, Shi YE: Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene. 1997, 14: 2767-2774. 10.1038/sj.onc.1201245.PubMed
99.
ten Hagen TL, Eggermont AM: Solid tumor therapy: manipulation of the vasculature with TNF. Technol Cancer Res Treat. 2003, 2: 195-203.PubMed
100.
Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C, Bayol N, Gillen M, Chu K, Rasmussen C, Rasmussen H, Kufe D, Weichselbaum R, Hanna N: TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol. 2004, 22: 592-601. 10.1200/JCO.2004.01.227.PubMed
101.
Grant SW, Kyshtoobayeva AS, Kurosaki T, Jakowatz J, Fruehauf JP: Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma. Cancer Detect Prev. 1998, 22: 185-194. 10.1046/j.1525-1500.1998.0oa18.x.PubMed
102.
Van Meir EG, Polverini PJ, Chazin VR, Su Huang HJ, de Tribolet N, Cavenee WK: Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet. 1994, 8: 171-176.PubMed
103.
Holmgren L, Jackson G, Arbiser J: p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma. Oncogene. 1998, 17: 819-824. 10.1038/sj.onc.1201993.PubMed
104.
Su JD, Mayo LD, Donner DB, Durden DL: PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. Cancer Res. 2003, 63: 3585-3592.PubMed
105.
Szary J, Szala S: Intra-tumoral administration of naked plasmid DNA encoding mouse endostatin inhibits renal carcinoma growth. Int J Cancer. 2001, 91: 835-839. 10.1002/1097-0215(200002)9999:9999<::AID-IJC1123>3.3.CO;2-K.PubMed
106.
Oga M, Takenaga K, Sato Y, Nakajima H, Koshikawa N, Osato K, Sakiyama S: Inhibition of metastatic brain tumor growth by intramuscular administration of the endostatin gene. Int J Oncol. 2003, 23: 73-79.PubMed
107.
Blezinger P, Wang J, Gondo M, Quezada A, Mehrens D, French M, Singhal A, Sullivan S, Rolland A, Ralston R, Min W: Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol. 1999, 17: 343-348. 10.1038/7895.PubMed
108.
Barron LG, Uyechi LS, Szoka F. C., Jr.: Cationic lipids are essential for gene delivery mediated by intravenous administration of lipoplexes. Gene Ther. 1999, 6: 1179-1183. 10.1038/sj.gt.3300929.PubMed
109.
Marty C, Odermatt B, Schott H, Neri D, Ballmer-Hofer K, Klemenz R, Schwendener RA: Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. Br J Cancer. 2002, 87: 106-112. 10.1038/sj.bjc.6600423.PubMedCentralPubMed
110.
Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN: Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol. 1997, 15: 647-652.PubMed
111.
Rodolfo M, Cato EM, Soldati S, Ceruti R, Asioli M, Scanziani E, Vezzoni P, Parmiani G, Sacco MG: Growth of human melanoma xenografts is suppressed by systemic angiostatin gene therapy. Cancer Gene Ther. 2001, 8: 491-496. 10.1038/sj.cgt.7700331.PubMed
112.
Chen QR, Kumar D, Stass SA, Mixson AJ: Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res. 1999, 59: 3308-3312.PubMed
113.
Thurston G, McLean JW, Rizen M, Baluk P, Haskell A, Murphy TJ, Hanahan D, McDonald DM: Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest. 1998, 101: 1401-1413.PubMedCentralPubMed
114.
Kondo M, Asai T, Katanasaka Y, Sadzuka Y, Tsukada H, Ogino K, Taki T, Baba K, Oku N: Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int J Cancer. 2004, 108: 301-306. 10.1002/ijc.11526.PubMed
115.
Janssen AP, Schiffelers RM, ten Hagen TL, Koning GA, Schraa AJ, Kok RJ, Storm G, Molema G: Peptide-targeted PEG-liposomes in anti-angiogenic therapy. Int J Pharm. 2003, 254: 55-58. 10.1016/S0378-5173(02)00682-8.PubMed
116.
Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen TM, Corti A, Ponzoni M: Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 2003, 63: 7400-7409.PubMed
117.
Gu ZP, Wang YJ, Li JG, Zhou YA: VEGF165 antisense RNA suppresses oncogenic properties of human esophageal squamous cell carcinoma. World J Gastroenterol. 2002, 8: 44-48.PubMed
118.
Im SA, Gomez-Manzano C, Fueyo J, Liu TJ, Ke LD, Kim JS, Lee HY, Steck PA, Kyritsis AP, Yung WK: Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res. 1999, 59: 895-900.PubMed
119.
Marchand GS, Noiseux N, Tanguay JF, Sirois MG: Blockade of in vivo VEGF-mediated angiogenesis by antisense gene therapy: role of Flk-1 and Flt-1 receptors. Am J Physiol Heart Circ Physiol. 2002, 282: H194-204.PubMed
120.
Shim WS, Teh M, Mack PO, Ge R: Inhibition of angiopoietin-1 expression in tumor cells by an antisense RNA approach inhibited xenograft tumor growth in immunodeficient mice. Int J Cancer. 2001, 94: 6-15. 10.1002/ijc.1428.PubMed
121.
Dallabrida SM, De Sousa MA, Farrell DH: Expression of antisense to integrin subunit beta 3 inhibits microvascular endothelial cell capillary tube formation in fibrin. J Biol Chem. 2000, 275: 32281-32288. 10.1074/jbc.M001446200.PubMed
122.
Lipscomb EA, Dugan AS, Rabinovitz I, Mercurio AM: Use of RNA interference to inhibit integrin (alpha6beta4)-mediated invasion and migration of breast carcinoma cells. Clin Exp Metastasis. 2003, 20: 569-576. 10.1023/A:1025819521707.PubMed
123.
Yang G, Cai KQ, Thompson-Lanza JA, Bast R. C., Jr., Liu J: Inhibition of Breast and Ovarian Tumor Growth through Multiple Signaling Pathways by Using Retrovirus-mediated Small Interfering RNA against Her-2/neu Gene Expression. J Biol Chem. 2004, 279: 4339-4345. 10.1074/jbc.M311153200.PubMed
124.
Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002, 296: 550-553. 10.1126/science.1068999.PubMed
125.
Zhang L, Yang N, Mohamed-Hadley A, Rubin SC, Coukos G: Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem Biophys Res Commun. 2003, 303: 1169-1178. 10.1016/S0006-291X(03)00495-9.PubMed
126.
Thomas CE, Ehrhardt A, Kay MA: Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003, 4: 346-358. 10.1038/nrg1066.PubMed
127.
Reynolds PN, Zinn KR, Gavrilyuk VD, Balyasnikova IV, Rogers BE, Buchsbaum DJ, Wang MH, Miletich DJ, Grizzle WE, Douglas JT, Danilov SM, Curiel DT: A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol Ther. 2000, 2: 562-578. 10.1006/mthe.2000.0205.PubMed
128.
Yotnda P, Chen DH, Chiu W, Piedra PA, Davis A, Templeton NS, Brenner MK: Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther. 2002, 5: 233-241. 10.1006/mthe.2002.0545.PubMed
129.
Logg CR, Kasahara N: Retrovirus-mediated gene transfer to tumors: utilizing the replicative power of viruses to achieve highly efficient tumor transduction in vivo. Methods Mol Biol. 2004, 246: 499-525.PubMed
130.
Rollins SA, Birks CW, Setter E, Squinto SP, Rother RP: Retroviral vector producer cell killing in human serum is mediated by natural antibody and complement: strategies for evading the humoral immune response. Hum Gene Ther. 1996, 7: 619-626.PubMed
131.
Ghazizadeh S, Carroll JM, Taichman LB: Repression of retrovirus-mediated transgene expression by interferons: implications for gene therapy. J Virol. 1997, 71: 9163-9169.PubMedCentralPubMed
132.
Smith-Arica JR, Bartlett JS: Gene therapy: recombinant adeno-associated virus vectors. Curr Cardiol Rep. 2001, 3: 43-49.PubMed
133.
White SJ, Nicklin SA, Buning H, Brosnan MJ, Leike K, Papadakis ED, Hallek M, Baker AH: Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation. 2004, 109: 513-519. 10.1161/01.CIR.0000109697.68832.5D.PubMed
134.
Giles J: Protests win reprieve for renowned medical lab. Nature. 2003, 423: 573-PubMed
135.
Kay MA, Nakai H: Looking into the safety of AAV vectors. Nature. 2003, 424: 251-10.1038/424251b.PubMed
136.
Shichinohe T, Bochner BH, Mizutani K, Nishida M, Hegerich-Gilliam S, Naldini L, Kasahara N: Development of lentiviral vectors for antiangiogenic gene delivery. Cancer Gene Ther. 2001, 8: 879-889. 10.1038/sj.cgt.7700388.PubMed
137.
Pfeifer A, Kessler T, Silletti S, Cheresh DA, Verma IM: Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc Natl Acad Sci U S A. 2000, 97: 12227-12232. 10.1073/pnas.220399597.PubMedCentralPubMed
138.
Latchman DS: Herpes simplex virus vectors for gene therapy. Mol Biotechnol. 1994, 2: 179-195.PubMed
139.
Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X, Samulski RJ: Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol. 2002, 76: 791-801. 10.1128/JVI.76.2.791-801.2002.PubMedCentralPubMed
140.
Khare PD, Liao S, Hirose Y, Kuroki M, Fujimura S, Yamauchi Y, Miyajima-Uchida H: Tumor growth suppression by a retroviral vector displaying scFv antibody to CEA and carrying the iNOS gene. Anticancer Res. 2002, 22: 2443-2446.PubMed
141.
Reynolds PN, Nicklin SA, Kaliberova L, Boatman BG, Grizzle WE, Balyasnikova IV, Baker AH, Danilov SM, Curiel DT: Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol. 2001, 19: 838-842. 10.1038/nbt0901-838.PubMed
142.
Varda-Bloom N, Shaish A, Gonen A, Levanon K, Greenbereger S, Ferber S, Levkovitz H, Castel D, Goldberg I, Afek A, Kopolovitc Y, Harats D: Tissue-specific gene therapy directed to tumor angiogenesis. Gene Ther. 2001, 8: 819-827. 10.1038/sj.gt.3301472.PubMed
143.
Thorpe PE: Vascular targeting agents as cancer therapeutics. Clin Cancer Res. 2004, 10: 415-427.PubMed
144.
Tozer GM, Kanthou C, Parkins CS, Hill SA: The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol. 2002, 83: 21-38. 10.1046/j.1365-2613.2002.00211.x.PubMedCentralPubMed
145.
Pasqualini R, Koivunen E, Ruoslahti E: Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol. 1997, 15: 542-546.PubMed
146.
Arap W, Pasqualini R, Ruoslahti E: Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998, 279: 377-380. 10.1126/science.279.5349.377.PubMed
147.
Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E: A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med. 2002, 8: 751-755.PubMed
148.
Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkila P, Kantor C, Gahmberg CG, Salo T, Konttinen YT, Sorsa T, Ruoslahti E, Pasqualini R: Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol. 1999, 17: 768-774. 10.1038/11703.PubMed
149.
Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA: Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell. 1996, 85: 683-693. 10.1016/S0092-8674(00)81235-0.PubMed
150.
Folkman J: Angiogenic zip code. Nat Biotechnol. 1999, 17: 749-10.1038/11676.PubMed
151.
Masson-Gadais B, Houle F, Laferriere J, Huot J: Integrin alphavbeta3, requirement for VEGFR2-mediated activation of SAPK2/p38 and for Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF. Cell Stress Chaperones. 2003, 8: 37-52. 10.1379/1466-1268(2003)8<37:IVRFVA>2.0.CO;2.PubMedCentralPubMed
152.
Marshall JF, Hart IR: The role of alpha v-integrins in tumour progression and metastasis. Semin Cancer Biol. 1996, 7: 129-138. 10.1006/scbi.1996.0018.PubMed
153.
Eliceiri BP, Cheresh DA: The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest. 1999, 103: 1227-1230.PubMedCentralPubMed
154.
Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ: Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med. 1998, 4: 408-414.PubMed
155.
Thomas GJ, Lewis MP, Whawell SA, Russell A, Sheppard D, Hart IR, Speight PM, Marshall JF: Expression of the alphavbeta6 integrin promotes migration and invasion in squamous carcinoma cells. J Invest Dermatol. 2001, 117: 67-73. 10.1046/j.0022-202x.2001.01379.x.PubMed
156.
Larocca D, Kassner PD, Witte A, Ladner RC, Pierce GF, Baird A: Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage. Faseb J. 1999, 13: 727-734.PubMed
157.
Poul MA, Marks JD: Targeted gene delivery to mammalian cells by filamentous bacteriophage. J Mol Biol. 1999, 288: 203-211. 10.1006/jmbi.1999.2678.PubMed
158.
Di Giovine M, Salone B, Martina Y, Amati V, Zambruno G, Cundari E, Failla CM, Saggio I: Binding properties, cell delivery, and gene transfer of adenoviral penton base displaying bacteriophage. Virology. 2001, 282: 102-112. 10.1006/viro.2000.0809.PubMed
159.
Burg MA, Jensen-Pergakes K, Gonzalez AM, Ravey P, Baird A, Larocca D: Enhanced phagemid particle gene transfer in camptothecin-treated carcinoma cells. Cancer Res. 2002, 62: 977-981.PubMed
160.
Moghimi SM, Hunter AC, Murray JC: Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001, 53: 283-318.PubMed
161.
Vinogradov SV, Bronich TK, Kabanov AV: Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv Drug Deliv Rev. 2002, 54: 135-147. 10.1016/S0169-409X(01)00245-9.PubMed
162.
Panyam J, Labhasetwar V: Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003, 55: 329-347. 10.1016/S0169-409X(02)00228-4.PubMed
163.
Anderson SA, Rader RK, Westlin WF, Null C, Jackson D, Lanza GM, Wickline SA, Kotyk JJ: Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn Reson Med. 2000, 44: 433-439. 10.1002/1522-2594(200009)44:3<433::AID-MRM14>3.0.CO;2-9.PubMed
164.
Artemov D, Mori N, Okollie B, Bhujwalla ZM: MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med. 2003, 49: 403-408. 10.1002/mrm.10406.PubMed
165.
Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA: Tumor regression by targeted gene delivery to the neovasculature. Science. 2002, 296: 2404-2407. 10.1126/science.1070200.PubMed
166.
Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003, 302: 415-419. 10.1126/science.1088547.PubMed
167.
Cavazzana-Calvo M, Thrasher A, Mavilio F: The future of gene therapy. Nature. 2004, 427: 779-781. 10.1038/427779a.PubMed
168.
Scappaticci FA: Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol. 2002, 20: 3906-3927. 10.1200/JCO.2002.01.033.PubMed
169.
Abdollahi A, Lipson KE, Sckell A, Zieher H, Klenke F, Poerschke D, Roth A, Han X, Krix M, Bischof M, Hahnfeldt P, Grone HJ, Debus J, Hlatky L, Huber PE: Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res. 2003, 63: 8890-8898.PubMed
170.
Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003, 349: 427-434. 10.1056/NEJMoa021491.PubMedCentralPubMed
171.
Abdollahi A, Hahnfeldt P, Maercker C, Grone HJ, Debus J, Ansorge W, Folkman J, Hlatky L, Huber PE: Endostatin's Antiangiogenic Signaling Network. Mol Cell. 2004, 13: 649-663. 10.1016/S1097-2765(04)00102-9.PubMed
172.
Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R: Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci U S A. 2003, 100: 4766-4771. 10.1073/pnas.0730882100.PubMedCentralPubMed
173.
Panka DJ, Mier JW: Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J Biol Chem. 2003, 278: 37632-37636. 10.1074/jbc.M307339200.PubMed
174.
Xu R, Xin L, Fan Y, Meng HR, Li ZP, Gan RB: Mouse restin inhibits bovine aortic endothelial cell proliferation and causes cell apoptosis. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2002, 34: 138-142.
175.
Corbacho AM, Martinez De La Escalera G, Clapp C: Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol. 2002, 173: 219-238.PubMed
176.
Bikfalvi A, Gimenez-Gallego G: The control of angiogenesis and tumor invasion by platelet factor-4 and platelet factor-4-derived molecules. Semin Thromb Hemost. 2004, 30: 137-144. 10.1055/s-2004-822978.PubMed
177.
Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001, 104: 487-501. 10.1016/S0092-8674(01)00237-9.PubMed
178.
O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J: Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science. 1999, 285: 1926-1928. 10.1126/science.285.5435.1926.PubMed
179.
Zhang M, Volpert O, Shi YH, Bouck N: Maspin is an angiogenesis inhibitor. Nat Med. 2000, 6: 196-199. 10.1038/72303.PubMed
180.
Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP: Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 1999, 285: 245-248. 10.1126/science.285.5425.245.PubMed
181.
Zhai Y, Yu J, Iruela-Arispe L, Huang WQ, Wang Z, Hayes AJ, Lu J, Jiang G, Rojas L, Lippman ME, Ni J, Yu GL, Li LY: Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer. 1999, 82: 131-136. 10.1002/(SICI)1097-0215(19990702)82:1<131::AID-IJC22>3.3.CO;2-F.PubMed
182.
Yu J, Tian S, Metheny-Barlow L, Chew LJ, Hayes AJ, Pan H, Yu GL, Li LY: Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor. Circ Res. 2001, 89: 1161-1167.PubMed
183.
Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P: 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell. 2003, 3: 363-375. 10.1016/S1535-6108(03)00077-1.PubMed
184.
185.
Sage EH, Reed M, Funk SE, Truong T, Steadele M, Puolakkainen P, Maurice DH, Bassuk JA: Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis. J Biol Chem. 2003, 278: 37849-37857. 10.1074/jbc.M302946200.PubMed
186.
Brekken RA, Sage EH: SPARC, a matricellular protein: at the crossroads of cell-matrix. Matrix Biol. 2000, 19: 569-580. 10.1016/S0945-053X(00)00105-0.PubMed
187.
Colman RW, Jameson BA, Lin Y, Johnson D, Mousa SA: Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood. 2000, 95: 543-550.PubMed
188.
Guo YL, Wang S, Colman RW: Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Arterioscler Thromb Vasc Biol. 2001, 21: 1427-1433.PubMed
189.
Zhang JC, Donate F, Qi X, Ziats NP, Juarez JC, Mazar AP, Pang YP, McCrae KR: The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. Proc Natl Acad Sci U S A. 2002, 99: 12224-12229. 10.1073/pnas.192668299.PubMedCentralPubMed
Metadata
Title
Antiangiogenic gene therapy of cancer: recent developments
Authors
Anita Tandle
Dan G Blazer III
Steven K Libutti
Publication date
01-12-2004
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2004
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-2-22

Other articles of this Issue 1/2004

Journal of Translational Medicine 1/2004 Go to the issue

Review

From bench to clinic and back: Perspective on the 1st IQPC Translational Research conference

Review

Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer

Commentary

Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?

Commentary

Cancer immunotherapy: avoiding the road to perdition

Research

Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer

Commentary

Granzyme B; the chalk-mark of a cytotoxic lymphocyte
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits